# Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy

## Grant Award Details

Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy

**Grant Type:** Clinical Trial Stage Projects

**Grant Number:** CLIN2-08334

**Project Objective:** To complete a Phase II clinical trial in Duchenne Muscular Dystrophy patients with cardiomyopathy, in which allogeneic Cardiosphere Derived Cells (CDCs) [aka CAP-1002] are infused one time via multi-vessel intracoronary delivery.

**Investigator:**

| | |
|---|---|
| **Name:** | Deborah Ascheim |
| **Institution:** | Capricor, Inc |
| **Type:** | PI |

**Disease Focus:** Heart Disease, Heart disease associated with Duchenne muscular dystrophy

**Human Stem Cell Use:** Adult Stem Cell

**Award Value:** $3,376,259

**Status:** Active

## Progress Reports

**Reporting Period:** Operational Milestone #1

**View Report**

## Grant Application Details

**Application Title:** Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy

| | |
|---|---|
| **Public Abstract:** | **Therapeutic Candidate or Device**<br><br>Allogeneic Cardiosphere-Derived Cells (CDCs, CAP-1002)<br><br>**Indication**<br><br>Duchenne Muscular Dystrophy Cardiomyopathy<br><br>**Therapeutic Mechanism**<br><br>Secretion of identified bioactive elements will reduce myocardial fibrosis and improve cardiac function.<br><br>**Unmet Medical Need**<br><br>Heart failure is the leading cause of death among young men with Duchenne Muscular Dystrophy. No specific therapies exist to treat this element of the disease. CAP-1002 is intended to treat the cardiomyopathy associated with DMD.<br><br>**Project Objective**<br><br>Phase 2 study completed<br><br>**Major Proposed Activities**<br><br>• manufacture CAP-1002 in quantities sufficient to treat all subjects enrolled in the trial<br>• enroll and treat all subjects per the clinical protocol<br>• enroll and treat all subjects per the clinical protocol |
| **Statement of Benefit to California:** | The applicant is a California-based organization. At least one clinical site within California will participate in the study. |

---

**Source URL:** https://www.cirm.ca.gov/our-progress/awards/allogeneic-cardiosphere-derived-cells-duchenne-muscular-dystrophy-cardiomyopathy